Date: Wednesday 23rd October 2024
Time: 14:00-16:00 BST | 15:00-17:00 CEST | 09:00-11:00 ET
Location: Online via Zoom
Speakers: Meg Gamalo (Pfizer), Cordula Zeller (Boehringer-Ingelheim), Patrick Schlömer (Bayer) and Dali Zhou (FDA).
Who is this event intended for? Statisticians with an interest in understanding the challenges and opportunities for hierarchical composite endpoints in drug development.
What is the benefit of attending? Learn about theory and application of hierarchical composite endpoints and their analysis methods (e.g., win ratio, win odds, net benefit) through presentations from statisticians in the industry and a regulatory discussant.
This event is free to both Members of PSI and Non-Members. To register your place for this event, please click here.
This upcoming webinar will discuss the complexities and opportunities of clinical trials with hierarchical composite endpoints, covering topics such as win odds, win ratio, net benefit as well as regulatory considerations when defining hierarchical composite endpoints. We’ll start this webinar with a general introduction to hierarchical composite endpoints and an overview of common analysis methods including win ratio, win odds, and net benefit. Then, the practical considerations will be illustrated through case studies from clinical trials in heart failure and chronic kidney disease. We conclude with a discussion and a Q&A. Join us to gain valuable insights and a comprehensive understanding of this topic.
Further information on our speakers will be released shortly.
This webinar will cover the history of cell/gene therapy, major regulatory advances, the role of quantitative scientists in drug development of these novel therapeutics, and discuss opportunities for innovation and product advancement.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
This 2-day course is designed to provide a comprehensive understanding of the regulatory guidelines affecting statisticians in the pharmaceutical industry, including the latest updates in the field. The course will cover key International Council for Harmonisation (ICH) guidelines and other key regional regulatory agency documents.
In this event, we’ll start with a general introduction to hierarchical composite endpoints and an overview of common analysis methods including win ratio, win odds, and net benefit. Then, the practical considerations will be illustrated through case studies from clinical trials in heart failure and chronic kidney disease. We conclude with a discussion and a Q&A.
A careers talk about medical statistics and how it plays a crucial role in developing new medicines
This webinar will discuss opportunities in applying causal inference methodology during the analysis of RCT data.
Lea Vaas will present how replacement of concurrent control animals by Virtual Control Groups (VCGs) in systemic toxicity studies may help in contributing to the 3R's principle of animal experimentation: Reduce, Refine, Replace.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
To provide expert statistical and strategic support to asset development programs in GSK Vaccines pipeline.
